P ersistent viral infections such as HIV and hepatitis C virus pose a severe health risk to the human population, which so far cannot be addressed by efficient prophylactic vaccination. Antiviral treatment is expensive and often associated with significant adverse effects. Therapeutic vaccination could therefore represent an important addition to current treatment modalities. However, vaccination of chronically infected hosts has mostly fallen short of expectations. One important reason for this is that during the development of a chronic infection, normal memory T cells do not develop. 1 Instead, some specificities of virusspecific T cells are eliminated while others develop into a dysfunctional cell type termed exhausted cells. These T cells are characterized by impaired capacity for proliferation, reduced ability to secrete effector cytokines and permanent upregulation of inhibitory receptors, of which PD-1 is probably the most well known. 2 Thus, based on studies in animal models like the chronic lymphocytic choriomeningitis virus (LCMV) clone 13 infection of mice, the effectiveness of therapeutic vaccination has been found to be limited by a low CD8 T-cell proliferative potential as well as a high viral load. 3 However, a number studies involving the application of antibodies directed toward key immune check point inhibitors have revealed that these alone and in particular in combination with therapeutic vaccination 4 may induce some measure of improved virus control in persistently infected animals. Interestingly, other ways to successfully impact virus control in chronically infected animals are treatment with exogenous IL-2 (ref. 5) and adoptive transfer of virus-specific CD4 T cells. 6 This goes nicely in line with the fact that despite that CD8 T cells are generally central in the control of viral infections, CD4 T cells are needed to maintain CD8 T-cell activity during prolonged infection, and their role in helping the antiviral antibody response may also be essential. 7 Indeed, transient depletion of CD4 T cells prior to clone 13 infection dramatically extends the course of the infection. 8 In the context of treatment of chronic infection, it is important to understand that exhausted T cells are not terminally differentiated cells, they maintain some capacity to limit virus replication, and upon inhibition of PD-1/PD-L1 interaction there is a marked expansion of functional effector T cells from a subset of exhausted CD8 T cells characterized by the expression of CXCR5, 9 demonstrating a potential for recovery of the antiviral immune response.
In their new study on therapeutic vaccination of mice chronically infected with LCMV clone 13, He et al. 10 takes advantage of these previously established facts and put to the test whether it is possible to improve virus control in chronically infected mice by the application of vaccines initially targeting only the CD4 T cells. A heterologous primeboost regimen was applied, which involved initial vaccination of chronically infected mice with a Listeria monocytogenes vector expressing the MHC class IIrestricted GP61-80 epitope 21 days after LCMV clone 13 infection followed by systemic boosting with an influenza A (PR8) vector expressing the same epitope 7 days later. This vaccination strategy resulted in a strong, polyfunctional LCMV-specific CD4 T-cell response, which was associated with increased numbers of virus-specific CD8 T cells of normal functionality. Most importantly, substantially improved virus control was also observed. Although vaccination in itself was quite effective, combining this with blockade of the PD-1 inhibitory pathway further augmented the induced CD8 T-cell response and also significantly improved virus control in the treated animals. Notably, vaccinated mice did not become clinically affected by the treatment as it might have been expected based from the marked decline in viral load (and hence infected cells). Although there are still several things that needs to be clarified, these results are very encouraging when it comes to exploit therapeutic vaccination of chronically infected humans as an alternative or addition to pharmaceutical antiviral treatment. In fact, the study may have implications beyond virally infected patients. A dysfunctional immune response and exhausted T cells are also a common finding in cancer patients, 11 and the current findings may therefore point to therapeutic vaccination targeting the CD4 T cells as a distinct possibility for treatment also in this patient group. Therefore, with these important implications in mind let us look at the weaknesses of the current study. A major limitation is imbedded in the authors' choice of infection model for their studies. Often, mice to be infected with LCMV clone 13 are depleted of CD4 T cells immediately prior to infection. This causes a more profound and stable immune disturbance and long-term persistent infection. 9 Without CD4 depletion, the perturbation of the T-cell response is more limited, and the infected mice typically control the peripheral infection within about 2-3 months. Given that the authors of the current report wanted to apply their vaccine to an environment with a remaining antiviral CD4 T-cell population, they could not perform CD4 depletion with the result that the vaccine was given to mice in which there is a significant ongoing response to the virus. The possibility is therefore that the reported type of vaccine approach will only work in hosts with substantial residual immune activity. This possible limitation clearly needs to be tested in another relevant model of chronic infection. It is also of some concern that it is not absolutely clear which effector mechanism(s) underlies the improved virus control in vaccinated mice. There are multiple changes to the antiviral immune response in vaccinated mice, which potentially could contribute to the improved virus control. The authors show that CD4 and CD8 T cells are both needed, but the role of the CD4 T cells is not clear. Do they function predominantly as effector cells on their rightthe cells clearly become more polyfunctional-, or do they primarily provide help to exhausted CD8 T-cell and virusspecific B cell, and in the latter cases what is the mediator(s) involved-IL-21? Further studies are needed to fully understand this aspect of the improved antiviral immune response in the vaccinated mice. Nevertheless, while there is clearly additional studies to be performed, the presented data from He et al., 10 point to new opportunities in the treatment of chronic viral infection (and possible cancer) that it is clearly relevant to pursue, and it will be exiting to follow the development in the future.
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